Top image

Our Research

Here you'll find information about our Flagship programs and other projects. Use the filters below to display research of interest using one of the three categories.
  • WHAT IS EnRICH? The EnRICH program is a prospective clinical cohort of 1000 patients with lung cancer, which aims to better define, treat and care for patients in Sydney Catalyst member hosp...
  • T2,T3 | Flagship 2 Pilot and Seed
    Very low-energy diet before surgery in obese patients undergoing partial liver excision: A pilot randomised control trial (Very Supple Trial)
    Obesity in Australia is an increasingly concerning issue in healthcare. Obesity has been shown to make abdominal surgery more technically challenging and is associated with poorer outcomes. St...
  • T2,T3 | Flagship 2 Pilot and Seed
    Ensuring the symptoms of vulnerable populations are known: Identifying patient barriers and facilitators to completing PROMs in cancer care
    In Australis there are over 300 separately identified languages spoken in homes, with over 20% of Australians speaking a language other than English. In some health care services, this equals a...
    PsychosocialImplementation research
  • T2,T3 | Flagship 2 Pilot and Seed
    Aerobic exercise training during chemotherapy infusion
    Cancer and its treatment often cause physical and psychological side effects. Exercise is well known to benefit people with cancer, especially during treatment. It can reduce side effects such ...
    Evidence into practiceKnowledge translationTreatmentExercise
  • T1,T2 | Flagship 2 Pilot and Seed
    Unraveling the metabolic link between the host and breast cancer disease progression
    Obese and diabetic patients have a far higher risk that lean, healthy people of getting breast cancer, and have worse outcomes when they do get cancer. These examples highlight the crucial and ...
    Breast CancerMetastasis
  • T1,T2 | Flagship 2 Pilot and Seed
    Intravital imaging to overcome pancreatic cancer resistance to immunotherapy
    Survival rates in pancreatic cancer have been at a low standstill (5-year survival of ~9%) for the last decades. There is therefore an urgent need to assess new treatment strategies to effecti...
    ImagingImmunotherapyPancreatic cancer
  • T1,T2 | Flagship 2 Pilot and Seed
    Exploring functional capabilities of immune cells in the Tumour microenvironment (TME) to determine patient responses to immunotherapy
    LAY SUMMARY Although immunotherapy has made a huge impact on cancer patient care, it is still unclear how immunotherapy actually works. It is believed that reinvigoration of T cells is likel...
  • T1,T2 | Flagship 2 Pilot and Seed
    HIFUn+ – Nanotechnology-Enhanced High Intensity Focused Ultrasound as the New Generation of Cancer Therapy: advancing HIFU towards mainstream, non-invasive cancer therapy
    Current medicine, predominated by surgery, chemo- and radiotherapy has only taken us so far in beating cancer. Immunotherapy benefits less than 20% of patients (1). Targeting and uptake of pre...
  • T1,T2 | Flagship 3 Scholarships & Awards
    Implications of Homologous Recombination Deficiency defects in Advanced Prostate Cancer
    The 5-year survival for patients treated with anti-PD-1 in NSCLC is ~16%. We currently have no reliable tool for predicting who will benefit from this relatively tolerable single drug, and who ...
    BiomarkersGenetics/genomicsImmunotherapyLung cancer
  • T2,T3 | Flagship 3 Scholarships & Awards
    Patient experience of uncertainty when undergoing genomic testing
    This project will aim to understand patient experience of uncertainty when having cancer genomic testing, using questionnaires and interviews to investigate types, levels, predictors and impac...